These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 2498537)

  • 1. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
    Pierce GF; Lusher JM; Brownstein AP; Goldsmith JC; Kessler CM
    JAMA; 1989 Jun; 261(23):3434-8. PubMed ID: 2498537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transfusion hepatitis and its sequelae in the treatment of hemophilia].
    Schimpf K
    Behring Inst Mitt; 1983 Aug; (73):111-7. PubMed ID: 6433878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on children. The anxiety factor.
    Gregory M; Foy F
    Nurs Times; 1988 Apr 20-26; 84(16):71-2. PubMed ID: 3130616
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hemophilia and acquired immunodeficiency].
    Allain JP
    Rev Prat; 1989 Dec; 39(30):2674-7. PubMed ID: 2515581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current clinical aspects in hemophilia treatment].
    Meili EO
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemophilia gene transfer: comparison with conventional protein replacement therapy.
    Ragni MV
    Semin Thromb Hemost; 2004 Apr; 30(2):239-47. PubMed ID: 15118935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates].
    Astermark J; Berntorp E; Stigendal L; Johnsson H
    Lakartidningen; 1998 Jan; 95(1-2):48-50. PubMed ID: 9458646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acquired immunodeficiency syndrome in persons with hemophilia.
    Levine PH
    Ann Intern Med; 1985 Nov; 103(5):723-6. PubMed ID: 2996407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired immunodeficiency syndrome, hepatitis, and haemophilia.
    Jones P
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1737-8. PubMed ID: 6416569
    [No Abstract]   [Full Text] [Related]  

  • 13. Coagulation factor VIII concentrates and the marketplace.
    Cash JD
    Lancet; 1988 Jun; 1(8597):1270. PubMed ID: 2897528
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
    Mosley JW
    Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
    McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
    Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supply and demand for hemophilia treatments-Systems-based approaches to mitigate the risk.
    Stoffman JM; Jackson S; Teitel J
    Transfus Apher Sci; 2018 Dec; 57(6):731-734. PubMed ID: 30391093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene therapy for hemophilia: feasible in principle but not yet clinically applicable].
    van der Eb MM; Schagen FH; van Ormondt H; Hoeben RC
    Ned Tijdschr Geneeskd; 1998 Apr; 142(15):840-4. PubMed ID: 9623157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic therapy for hemophilia in a developing country, Turkey.
    Kavakli K; Nişli G; Aydinok Y; Oztop S; Cetingül N; Aydoğdu S; Yalman O
    Pediatr Hematol Oncol; 1997; 14(2):151-9. PubMed ID: 9089743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.